SG/CALL/ELI LILLY & CO/400/0.1/20.09.24 | Delayed Deutsche Boerse AG 19:06:21 17/06/2024 BST | ||
| 45.9 EUR | +1.37% |
|
| Current month | +16.22% | ||
| 1 month | +32.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 17/06/24 | 45.9 | +1.37% |
| 14/06/24 | 45.28 | -0.18% |
| 13/06/24 | 45.36 | +4.08% |
| 12/06/24 | 43.58 | -1.09% |
| 11/06/24 | 44.06 | +1.26% |
Delayed Quote Deutsche Boerse AG
Last update June 17, 2024 at 07:06 pm
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ8Z8K |
| ISIN | DE000SQ8Z8K7 |
| Date issued | 13/02/2023 |
| Strike | 400 $ |
| Maturity | 20/09/2024 (95 Days) |
| Parity | 10 : 1 |
| Emission price | 3.68 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 46.21 € |
|---|---|
| Lowest since issue | 2.34 € |
| Delta | 0x |
| Omega | 0.000000 |
| Premium | 0x |
| Gearing | 0x |
| Moneyness | 2.222 |
| Difference Strike | -488.4 $ |
| Difference Strike % | -122.09% |
| Intrinsic value | 45.58 |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
878.4
USD
Average target price
855.4
USD
Spread / Average Target
-2.63%
- Stock Market
- Warrants
- Warrant
